Skip to Content

IQVIA Holdings Inc

IQV: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$185.00XtzlwnnRqdyltctn

Positive Long-Term Outlook for IQVIA as Clinical Trial Outsourcing Demand Drives Growth

Business Strategy and Outlook

IQVIA (formerly QuintilesIMS) is the result of the merger of Quintiles, a leading late-stage contract research organization, or CRO, and IMS Health, a dominant player in life sciences data and analytics. The combined company has become a leader among CROs and in the life sciences data and analytics industry. Further, as a result of the merger, the company leads in real-world evidence, in which data from sources such as patient records or medical claims can be used to create clinical evidence for regulatory approval.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of IQV so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center